Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2289325 | 1.00 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL2293014 | 1.00 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| Hydrochloric Acid SCHEMBL2293011 | 1.00 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL2289331 | 0.99 | LTA4H (0.58) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL2411412 | 0.99 | LTA4H (0.58) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL16919769 | 0.98 | LTA4H (0.57) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL23425420 | 0.93 | SIRT2 (0.55) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL30541877 | 0.93 | LTA4H (0.53) | LTA4HMMP2ECE1LNPEPERAP2 | |
| SCHEMBL10459444 | 0.92 | MMP2 (0.58) | LTA4HMMP2ECE1CTSLANPEP | |
| SCHEMBL10459445 | 0.92 | MMP2 (0.58) | LTA4HMMP2ECE1CTSLANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160222384-A1 | Compositions for Targeted Delivery of siRNA | ARROWHEAD MADISON INC (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3023495-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | Arrowhead Research Corporation (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9345775-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-20150202298-A1 | Compositions for Targeted Delivery of siRNA | Arrowhead Pharmaceuticals, Inc. | 2015-07-23 | — | — | US | disclosed |
| US-9011919-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2652134-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130245091-A1 | Compositions for Targeted Delivery of siRNA | Arrowhead Madison Inc. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2539451-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | Arrowhead Research Corporation (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8313772-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011104169-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222384-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
| US-20150202298-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | GALK1, GALE, GALNT6 | LTA4H 4116/4885MMP2 3533/4885ECE1 3585/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | LTA4H 4116/4885MMP2 3533/4885ECE1 3585/4885 |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
| US-20130245091-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LTA4H 4372/4885MMP2 1318/4885ECE1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.